International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar–Apr 2025, pp: 2453-2462 www.ijprajournal.com ISSN: 2456-4494

Advancement in Drug Event Monitoring: Enhancing Patient Safety and Pharmacovigilance

Prof.(Dr.)Mohd.Wasiullah[1],Prof.(Dr.)PiyushYadav[2], Mr. Mohit Vishwakarma*[3], Mohammad Aquif Sheikh[4]

[1]*Principal, Dept. of Pharmacy, Prasad Institute of Technology, Jaunpur (222001) U.P., India*
[2]*AcademicHead,Dept.of Pharmacy,Prasad Institute of Technology,Jaunpur(2220001)U.P.,India*
[3]*Assistant Professor, Dept. of Pharmacy, Prasad Institute of Technology, Jaunpur (222001) U.P., India*
[4]*Scholar,Dept.ofPharmacy,PrasadInstituteofTechnology,Jaunpur(222001)U.P.,India*

Date of Submission: 20-04-2025 Date of Acceptance: 30-04-2025

ABSTRACT
Drug Event Monitoring (DEM) is a vital aspect of pharmacovigilance, enabling the continuous assessment of drug safety in real-world settings. With the rise of big data and artificial intelligence (AI), DEM is evolving into a more proactive, predictive, and efficient system. AI technologies, including machine learning and natural language processing, enhance adverse drug reaction detection, automate routine tasks, and support real-time monitoring. Complemented by network pharmacology and patient-centric approaches, these innovations improve the understanding of drug interactions and safety outcomes. Despite challenges in data quality and regulatory compliance, the integration of human expertise with advanced technologies is shaping a safer and more responsive future for pharmacovigilance.

KEYWORDS: Drug Event Monitoring (DEM)Pharmacovigilance Artificial Intelligence (AI) Adverse Drug Reactions (ADRs), Drug safety ,Health care outcome

III. INTRODUCTION

Drug Event Monitoring (DEM) is a crucial aspect of pharmacovigilance, involving the systematic collection, analysis, and interpretation of data related to adverse drug reactions (ADRs) and other drug-related events in real-world clinical settings. This observational study method is employed to monitor the safety and effectiveness of pharmaceutical products after they have been approved for use in the general population. DEM provides insights into how drugs perform in everyday medical practice across diverse patient populations, aiming to detect rare, long-term, or unexpected adverse events that may not have been identified during pre-market clinical trials due to limited sample sizes and controlled environments.

DEM operates through a structured framework where patient data is collected from various sources, including electronic health records (EHRs), prescription databases, healthcare professionals, and sometimes direct patient reporting. These data sources help in evaluating the drug's safety profile, allowing regulatory authorities and pharmaceutical companies to take necessary actions such as updating drug warnings, restricting usage, or even withdrawing a drug from the market if severe risks are identified. DEM is particularly useful for newly introduced drugs, as it enables early detection of safety concerns that could pose risks to public health.

Data collection in DEM can be active or passive. Active monitoring involves direct follow-ups with patients or healthcare providers through surveys, interviews, or electronic tracking systems, while passive monitoring relies on spontaneously reported adverse events from healthcare professionals or patients. Each method has its advantages and limitations, with active monitoring being more resource-intensive and time-consuming, and passive monitoring being cost-effective and easier to implement but may suffer from underreporting and biases. A combination of both approaches is often used to enhance the reliability of the collected data.

The implementation of DEM involves collaboration among multiple stakeholders, including regulatory agencies like the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), the World Health Organization (WHO), pharmaceutical companies, healthcare providers, and research institutions. The data obtained through DEM can lead to regulatory actions such as issuing safety alerts, revising drug labels, restricting indications, or conducting further studies to assess risks.

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar–Apr 2025, pp: 2453-2462 www.ijprajournal.com ISSN: 2456-4494

Importance of pharmacovigilance in health care

Pharmacovigilance (PV) is a vital discipline in drug development and healthcare, focusing on the detection, assessment, understanding, and prevention of adverse effects or other medicine/vaccine-related problems. Its primary objective is to protect patient welfare and public health by identifying and analyzing potential risks linked to pharmaceutical products[1] PV plays a key role in shaping drug access policies and conducting health technology assessments, defining a drug's safety profile, facilitating informed decision-making for healthcare professionals and regulatory authorities, and enhancing public trust in the healthcare system. It also contributes to benefit-risk (BR) assessments both before and after a drug is marketed, serving the best interests of patients. The necessity for specialized professionals to oversee and manage drug safety became evident with the advent of modern medicine and advancements in pharmacology. The thalidomide disaster of the 1950s and 1960s highlighted the urgent need for stringent safety monitoring and regulatory frameworks. Despite its origins dating back nearly 170 years, PV has a significant social and economic impact, aiming to assess drug risk-benefit ratios, improve patient safety, and elevate the quality of life. Understanding the historical progression of PV allows us to appreciate its significant achievements in human health and pharmaceutical science while preparing for future challenges.[2]

Year	Evolution
1747	First clinical trial by James Lind to prove the effect of lemon juice in treatment of scurvy.
1937	Demise of 100+ infants due to sulphanilamide toxicity.
1950	Reported aplastic anemia due to chloramphenicol toxicity.
1961	Global catastrophe by thalidomide toxicity.
1963	Recollection of immediate action on ADRs by World Health.
1968	WHO researches for global drug monitoring on pilot scale.
1996	International standard level clinical trials introduced in India.
1997	India merged with WHO ADR monitoring program.
1998	Commencement of pharmacovigilance in India.
2002	67th National Pharmacovigilance Centre was vested in India.
2004-2005	National Pharmacovigilance Program was established in India.
2009-2010	PvPI (Pharmacovigilance Program) was commenced.
2012	Haemovigilance was started.
2015	Commencement of MvPI (Materiovigilance).

Adverse drug reaction

The World Health Organization (WHO) defines adverse drug reactions (ADRs) as a response to a noxious and unintended drug that occurs at doses normally used in humans for prophylaxis, diagnosis, therapy, or modification of physiological function. Between 1961 and 1962, the use of thalidomide by pregnant women led to birth defects in approximately ten thousand children worldwide.[3] This tragedy prompted the WHO to establish the Program for International Drug Monitoring (PIDM) in 1968 to facilitate early identification of ADRs. Today, this initiative is known as pharmacovigilance, overseen by the Uppsala Monitoring Centre (UMC) in Sweden. It is crucial to document and report unexpected medical events in all settings where medications are used, as adverse drug reactions can occur at any dose, including overdoses, and through misuse or abuse. ADR monitoring is a fundamental component of quality assurance departments within healthcare systems in developed nations, helping to identify new reactions, track their frequency, evaluate risk factors, and provide information to prescribers to prevent future ADRs.[4]

Advancement in technology innovation for drug event monitoring

Artificial intelligence and big data are transforming the way we approach drug safety.

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar–Apr 2025, pp: 2453-2462 www.ijprajournal.com ISSN: 2456-4494

With the growing complexity of healthcare data, traditional methods for spotting adverse drug reactions and monitoring safety are struggling to keep up. AI tools, like natural language processing and deep learning, are stepping in to make these processes faster, smarter, and more proactive. They're helping us understand drug safety on a whole new level.[5] But as we embrace these innovations, it's important to take a step back and ask: what do we still need, what's working well, and where are the gaps? By looking at the current landscape critically, we can better shape the future of pharmacovigilance.

Artifical Intelligence

Artificial intelligence (AI) and big data play a vital role in pharmacovigilance by helping to manage and interpret huge amounts of information from different sources. Advanced AI and machine learning methods, such as natural language processing and deep learning, can automate the collection and review of adverse drug reactions (ADRs), making the detection process faster and more precise. Continuous monitoring of drug safety is also important, especially for patients taking multiple medications or those from diverse backgrounds. AI-powered tools can better identify and predict drug interactions and complex ADRs by analyzing large datasets and uncovering patterns that traditional approaches might miss.[6]

AI and smart automation can greatly enhance pharmacovigilance workflows by handling repetitive tasks, such as initial case report checks, confirming regulatory details, and evaluating case accuracy. This reduces the burden on healthcare professionals, allowing them to focus on more critical work. Additionally, integrating AI into telehealth systems enables ongoing monitoring of ADRs in remote patients using data from wearable devices and virtual consultations. For instance, health agencies in France have used AI systems to support COVID-19 vaccine safety monitoring.[7]SS

AI Technologies in pharmacovigilance

AI technologies are being integrated into pharmacovigilance systems to improve patient safety. Machine Learning (ML) is used for adverse event detection, analyzing vast datasets from electronic medical records, clinical trial data, and patient reports to identify patterns and predict future adverse drug reactions (ADRs). This helps pharmaceutical companies and regulatory agencies respond faster than traditional methods, minimizing harm to patients.

Natural Language Processing (NLP) is used for data extraction, detecting potential ADRs in unstructured data like patient narratives, doctor notes, and social media posts. NLP tools can scan scientific literature, medical reports, and patient feedback to detect potential ADRs, allowing for more comprehensive drug safety surveillance.[8]

Automation in case processing and signal detection streamlines traditional processes by classifying and prioritizing cases based on severity and potential risk. AI systems can also assist in signal detection, identifying new safety concerns related to a drug.

Predictive analytics uses AI to forecast potential safety issues before they become widespread. By analyzing historical data, genetic factors, patient demographics, and drug interactions, AI can predict which patients are more likely to experience adverse reactions. [9]This personalized approach to medicine significantly enhances patient safety.

AI-driven chatbots are being integrated into pharmacovigilance systems to engage with patients and collect real-time feedback on drug effects. These chatbots can interact via mobile apps, reminding them to report side effects and providing valuable insights into medication safety. By automating patient interactions, AI ensures that adverse events are reported promptly, allowing for quicker action and providing accurate drug information, reducing the risk of medication errors.[10]

Benefit of AI in pharmacovigilance

AI has numerous benefits in pharmacovigilance, including improved efficiency, enhanced accuracy, cost reduction, proactive risk management, and better compliance with drug safety regulations. Machine learning models can process vast amounts of data faster than human analysts, reducing the time required for adverse event detection.[11] They can identify subtle patterns that may be missed by traditional methods, leading to more accurate safety assessments. Automating pharmacovigilance tasks reduces operational costs while maintaining high safety standards. AI also aids in early detection and prediction of adverse events, enabling proactive interventions before widespread harm occurs. However, AI implementation presents challenges such as data quality and bias, regulatory compliance, interpretability and transparency,

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar–Apr 2025, pp: 2453-2462 www.ijprajournal.com ISSN: 2456-4494

integration with existing systems, and ensuring patient data privacy.[12] Despite these challenges, AI is increasingly being encouraged by regulatory agencies for improved monitoring and compliance with drug safety regulations.

AI implementation in pharmacovigilance faces several challenges, including data quality and bias, regulatory compliance, interpretability and transparency, integration with existing systems, and patient data privacy. High-quality, unbiased data is crucial for AI models to function effectively, and incomplete or biased datasets can lead to inaccurate predictions and safety concerns[13]. AI must comply with FDA and EMA guidelines to ensure patient safety and data privacy. AI-driven decisions should be interpretable by humans, and integrating AI with legacy systems can be complex. Ensuring AI tools adhere to privacy regulations is crucial for protecting patient information.

Network Pharmacovigilance in Drug event monitoring

Network pharmacology is a multidisciplinary field that combines systems biology, bioinformatics, and pharmacology to study drug actions at a systemic level. It focuses on multiple interactions within biological networks, recognizing that drugs often act on multiple targets, influencing pathways and molecular interactions. This approach helps researchers understand drug mechanisms, identify potential adverse effects, and predict drug-drug interactions (DDIs) at a systemic level.[14]

Roles of Network Pharmacology in Pharmacovigilance:

Network pharmacology plays a crucial role in pharmacovigilance by offering new methods to assess drug safety and effectiveness. Some key contributions of network pharmacology to pharmacovigilance include:

1. **Identification of Drug Targets and Off-Targets:** A fundamental aspect of pharmacovigilance is understanding how a drug interacts with biological systems. Network pharmacology helps in mapping drug targets and off-targets using databases such as DrugBank, STITCH, and ChEMBL. Identifying off-target effects can provide early warning signs of adverse reactions before a drug reaches widespread clinical use.
2. **Predicting Adverse Drug Reactions (ADRs):** By integrating drug-target interaction networks with disease-related pathways, network pharmacology can predict potential ADRs. Computational modeling of protein-protein interaction (PPI) networks helps in identifying unintended interactions that might lead to toxicity. This proactive approach reduces the reliance on post-marketing surveillance alone, facilitating early interventions.
3. **Drug Repurposing and Safety Profiling:**Network pharmacology aids in drug repurposing by analyzing similarities between drugs at the molecular level. Drugs with similar target interaction profiles can be repurposed for new indications, reducing development costs and time. Moreover, safety profiling through network-based methods can ensure that repurposed drugs do not exhibit harmful effects in new therapeutic applications.
4. **Understanding Drug-Drug Interactions (DDIs):** DDIs are a significant concern in pharmacovigilance as they can lead to severe adverse effects. Network pharmacology employs computational approaches to construct drug-drug interaction networks, predicting possible harmful interactions before clinical cases arise. Integrating such predictions with electronic health records (EHRs) and real-world data can enhance the accuracy of pharmacovigilance systems.[15]

Challenges and future direction

Network pharmacology, despite its benefits, faces challenges such as the integration and standardization of diverse biological and pharmacological data, the complexity of biological systems, and ethical and regulatory considerations associated with data mining and AI-driven pharmacovigilance. Ensuring data privacy, transparency, and reliability is crucial for regulatory decision-making. The future of network pharmacology in pharmacovigilance will likely involve greater integration with AI and machine learning algorithms, which can enhance predictive modeling, automate drug safety assessments, and detect emerging adverse drug reactions (ADR patterns). Collaborations between pharmaceutical companies, regulatory agencies, and academic institutions will be essential for refining network-based pharmacovigilance methodologies.[16]

Enhancing patient safety in drug event monitoring

The patient-centered approach in drug safety is becoming increasingly important, with patients increasingly reporting adverse events (AEs) directly to regulatory authorities or through

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar–Apr 2025, pp: 2453-2462 www.ijprajournal.com ISSN: 2456-4494

patient support programs. However, interpreting these events accurately requires critical thinking skills. PV physicians must promptly follow up with AE reporters using well-structured and precisely worded questions to ensure effective data collection and proper analysis. The patient-centered approach is also gaining prominence in benefit-risk assessments through careful documentation of patient preferences. PV physicians should actively engage with healthcare professionals, patients, and advocacy groups to promote patient-centric drug safety strategies. Healthcare professionals provide real-world insights into drug safety and efficacy in clinical settings, while patients offer unique perspectives based on their experiences. Advocacy groups represent patient interests and raise awareness of safety concerns. By collaborating with these stakeholders, PV physicians can gain diverse insights and reinforce patient-centered approaches in PV. However, inaccurate data can lead to unnecessary fears and misinformation,[17] especially during health crises. Striking a balance between leveraging valuable insights from collaboration with stakeholders and ensuring safety data remains accurate and evidence-based is crucial.

Increased focused on structural benefit risk assessment

The shift towards patient-centered drug development has led to significant improvements in regulatory guidelines for structured benefit-risk (BR) assessment frameworks. These frameworks aim to improve transparency in industry and regulatory decision-making when evaluating BR profiles. BR assessment is expected to be a continuous process throughout a product's life cycle. Quantitative BR evaluation using modeling techniques like Multiple-Criterion Decision Analysis (MCDA) has emerged as an option for integrating safety data within a product's benefit assessment. These techniques provide context to safety data, enabling the inclusion of patient preference information in the BR evaluation and decision-making process. Patient preference data involves gathering insights into BR trade-offs, measuring the level of risk patients are willing to accept in exchange for specific anticipated benefits. PV physicians must develop an understanding of these innovative methodologies to avoid assessing safety data in isolation and accurately interpret their results.[18]

Significance of pharmacokinetic and pharmacodynamic in Drug safety :

Pharmacokinetics and pharmacodynamics are essential for physicians to evaluate drug safety profiles and ensure appropriate medication use in clinical settings. Key areas of focus include drug absorption, distribution, metabolism, receptor interactions, therapeutic index, and variations in drug response across different populations. Understanding receptor occupancy levels is crucial for determining safe dosage ranges in drug development. The therapeutic index, representing the ratio between the minimum effective dose and the dose linked to toxicity, is instrumental in establishing safe dosage parameters. Knowledge of drug absorption characteristics helps refine dosing strategies, and understanding a drug's receptor targets can help differentiate between adverse drug reactions (ADRs) caused by on-target or off-target effects. PK/PD data can provide valuable insights for drug safety efforts, such as ensuring therapeutic concentrations are achieved at target sites, predicting potential drug interactions, and modifying doses for patients with compromised renal or hepatic function. Recognizing inter- and intra-individual variations in PK/PD enables the development of personalized dosing recommendations, ensuring drug safety across diverse patient groups. However, current pharmacological models may not be entirely applicable to biologics, gene therapies, and cell-based treatments, highlighting the need for further research in these evolving therapeutic areas.[19]

Use of meta analysis of Randomized clinical trial in Drug safety :

Meta-analysis is a systematic review and statistical analysis of data from multiple randomized clinical trials (RCTs) to evaluate treatment effects. It is often used in pharmacovigilance due to the limited availability of product-related adverse drug reactions (ADRs). This approach allows for a larger sample size, enhancing statistical power to detect rare ADRs. [20]Meta-analyses provide valuable insights into a product's overall safety profile, supporting evidence-based decision-making in drug safety evaluations. However, post hoc meta-analyses assessing suspected safety concerns are increasingly being published, gaining media attention and influencing clinical practice and regulatory decision-making. These studies are prone to biases typical of retrospective observational studies, and discrepancies between

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar–Apr 2025, pp: 2453-2462 www.ijprajournal.com ISSN: 2456-4494

findings from meta-analyses and large RCTs highlight their limitations in drug safety assessments. The Consolidated Standards of Reporting Trials (CONSORT) Group has introduced new recommendations to address issues arising from inadequate reporting in RCTs, aiming to improve comprehensive documentation of ADR evidence. PV physicians must understand these methodological challenges and their implications for interpreting data, as assessing the impact of various methodological factors relies primarily on medical judgment, while statistical considerations play a secondary role.[21]



Figure : Advancements in Drug event Monitoring (DEM) and Enhancing Patient Safety.

Challenges and Limitation in Drug event monitoring

Underreporting, failure to report adverse drug reactions (ADRs) to regulatory authorities or pharmacovigilance systems, significantly impacts post-marketing drug safety monitoring. This issue affects the accuracy of safety profiles for marketed medications and reduces the effectiveness of pharmacovigilance systems.[22] Healthcare professionals often face obstacles in spontaneous ADR reporting, such as time constraints and lack of awareness. Studies in Africa and Southeast Asia have shown high prevalence of underreporting due to limited awareness, restricted access to reporting mechanisms, and legal concerns. [23]These findings underscore the need for customized interventions tailored to different healthcare environments.

Health care professional role

Healthcare professionals face challenges in reporting adverse drug reactions (ADRs) due to their demanding schedules and lack of awareness about the importance of reporting. Providing sspontaneous reporting programs still face challenges such as diagnosing ADRs, underreporting, and biases.[24] Innovative strategies and online signal detection tools are needed to raise awareness among healthcare professionals. Factors contributing to underreporting include fear of legal repercussions, misconceptions about reporting obligations, and limited time.

Progress in low and middle income country (LMICs)

Low- and middle-income countries (LMICs) are implementing national pharmacovigilance systems and cohort event monitoring for post-marketing surveillance. Artificial intelligence (AI) technologies have optimized pharmacovigilance processes, particularly in self-medication areas. AI can identify unrecorded adverse events (ADRs) and increase reporting rates. Recent advancements in AI have transformed pharmacovigilance globally, with machine learning algorithms accurately detecting adverse events from Electronic Health Records (EHRs) and natural language processing (NLP) enabling automated extraction of ADR data from unstructured sources. However, challenges remain, including high implementation costs, high-

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar–Apr 2025, pp: 2453-2462 www.ijprajournal.com ISSN: 2456-4494

quality datasets, technical expertise shortage, and concerns about data privacy and security. A collaborative effort between governments, healthcare organizations, and technology providers is needed to ensure AI-driven pharmacovigilance systems are effective and sustainable.[25,26]

Patient involvement and technological challenges

Patients often underreport adverse drug reactions (ADRs) due to their hesitation in informing doctors, forgetfulness, and providing inaccurate details. To promote timely reporting, educate patients during medication administration and raise awareness through strategies like role-playing exercises, set induction techniques, or counseling sessions at Primary Healthcare Centers, Rural Health Centers, and Urban Health Centers[27]. However, technical challenges in data collection, cleaning, and analysis require skilled professionals and a standardized database.[28] In Europe, initiatives like the Yellow Card Scheme and patient counseling sessions at community pharmacies have successfully improved reporting rates[29,30] These examples highlight the importance of equipping patients with knowledge and resources to actively participate in pharmacovigilance efforts.

Current trend and future prespective

Drug event monitoring has evolved significantly due to technological advancements, big data analytics, and increased regulatory focus on patient safety[31] Pharmacovigilance, the science of detecting, assessing, understanding, and preventing adverse effects or drug-related problems, has seen transformative changes with the integration of artificial intelligence (AI), real-world data (RWD), and patient-centric approaches[32]. The landscape of drug safety monitoring is shifting from a reactive to a proactive system, ensuring better patient outcomes and minimizing drug-related risks. AI and machine learning are key trends in drug event monitoring, enabling real-time data processing from multiple sources, such as electronic health records (EHRs), social media, and wearable health devices.[33] Big data analytics has further revolutionized pharmacovigilance by integrating structured and unstructured data from diverse sources, allowing researchers to identify patterns and trends in adverse drug reactions (ADRs).[34]

The use of natural language processing (NLP) in analyzing patient narratives, clinical notes, and social media posts has provided new insights into drug safety issues. Real-world evidence (RWE), derived from observational studies, patient registries, and insurance claims data, provides a more comprehensive understanding of a drug's safety profile across diverse demographics and clinical settings. Regulatory agencies like the FDA and EMA are increasingly incorporating RWE into their decision-making processes, leading to more dynamic and responsive drug safety assessments.[35,36]

Patient-centric approaches have gained momentum in drug event monitoring, with mobile health applications and digital health platforms allowing patients to report adverse drug reactions (ADRs) directly.[37] Wearable devices that track physiological parameters can provide real-time safety monitoring, alerting healthcare providers to potential adverse reactions before they become severe. Blockchain technology enhances transparency and security in pharmacovigilance by creating immutable records of drug safety data, improving data integrity, reducing fraud, and streamlining regulatory reporting.

Personalized pharmacovigilance is expected to become a key focus area, as advances in genomics and precision medicine enable healthcare providers to predict individual responses to specific drugs based on their genetic makeup. [38,39This proactive approach can minimize ADRs and optimize treatment plans, ensuring safer and more effective drug therapies.[40]

Regulatory frameworks are evolving to keep pace with these advancements, with AI-driven pharmacovigilance tools prompting guidelines for algorithm transparency, validation, and ethical considerations. Global collaborations like the International Coalition of Medicines Regulatory Authorities (ICMRA) are working towards harmonizing drug safety regulations across different countries. As technology continues to evolve, the future of pharmacovigilance will likely become more predictive, personalized, and proactive, leading to safer and more effective healthcare solutions for patients worldwide.[41]

IV. CONCLUSION

In conclusion, the integration of artificial intelligence, machine learning, big data, and natural language processing is fundamentally transforming pharmacovigilance, enabling more accurate, timely, and proactive drug safety monitoring. These technologies enhance the detection of adverse drug

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar–Apr 2025, pp: 2453-2462 www.ijprajournal.com ISSN: 2456-4494

reactions and drug-drug interactions, providing critical support for clinical decision-making and regulatory oversight. However, the full potential of this transformation can only be realized through ongoing improvements in data quality, algorithm transparency, and regulatory standards. Importantly, human expertise remains essential—ensuring that AI-driven insights are critically evaluated and responsibly applied. As pharmacovigilance continues to evolve, the synergy between advanced technology and skilled professionals will be key to achieving safer, more effective pharmacotherapy.

REFERENCE :

[1]. Rampurawala, Mubaraka& Shah, Chainesh& Upadhyay, Umesh. (2022). Pharmacovigilance: New Perspective for Drug Safety & Monitoring. 8.IJARIIE-ISSN(O)-2395-4396. 1424.

[2]. Drosten C (2023) Advancements in Pharmacovigilance Algorithms through Drug-Drug Interaction Monitoring. J Pharmacovigil. 11: 450.

[3]. Fornasier, G., Francescon, S., Leone, R., and Baldo, P. (2018). An historical overview over Pharmacovigilance. Int. J. Clin. Pharm. 40, 744–747. doi:10.1007/s11096-018-0657-1

[4]. Kim, James H., and Scialli, Anthony R. (2011). Thalidomide: the tragedy of birth defects and the effective treatment of disease. Toxicol. Sci. 122 (1), 1–6. doi:10.1093/toxsci/kfr088

[5]. Rajkumar Soni, Bikrant Kesari, A review in pharmacovigilance.(2014) 26(2). 237-241.

[6]. World Health Organization. The importance of pharmacovigilance – safety monitoring of medicinal products. World Health Organization, Geneva, 2002.

[7]. Ghosh Rupanwita, Bhatia M.S. and Bhattacharya S.K., " Pharmacovigilance: M aster Key to Drug Safety monitoring and its Status in India" , Delhi Psychiatry Journal, 15, October 2012, 412-415.

[8]. Kulkarni M .D., Baig M .S., Chandaliya K.C., Doifode S.M ., Razvi S.U., Sidhu N.S., "Knowledge, Attitude and Practice of Pharmacovigilance among Prescribers of Government Medical College and Hospital, Aurangabad (Maharashtra), international journal of pharmacology and therapeutics, 3, 2013, 10-18.

[9]. Mandal, Subhash. (2017). Evolution of Pharmacovigilance Programme: Present status in India. Pharmatimes. 49. 31-36.

[10]. World Health Organization. (2000) . WHO medicines strategy : framework for action in Essential Drugs and Medicines Policy 2000-2003. World Health Organization.

[11]. Olsson S. The role of the WHO programme on International Drug Monitoring in coordinating worldwide drug safety efforts. Drug Saf. 1998 Jul;19(1):1-10. doi: 10.2165/00002018-199819010-00001. PMID: 9673854.

[12]. Coulter DM. The New Zealand intensive medicines monitoring programme in pro-active safety surveillance. Pharmacoepidemiol Drug Saf. 2000 Jul;9(4):273-80. doi: 10.1002/1099-1557(200007/08)9:4<273::AID-PDS512>3.0.CO;2-T. PMID: 19025828.

[13]. Mackay FJ. Post-marketing studies: the work of the Drug Safety Research Unit. Drug Saf. 1998 Nov; 19(5):343-53. doi: 10.2165/00002018-199819050-00002. PMID: 9825948.

[14]. Folb, P. I. (1995). Drug monitoring in developing countries: A drug regulator's perspective. Drug Information Journal, 29(1), 303–305.

[15]. Talbot JC, Nilsson BS. Pharmacovigilance in the pharmaceutical industry. Br J Clin Pharmacol 1998;45:427-31.

[16]. Moore N. The role of the clinical pharmacologist in the management of adverse drug reactions. Drug Saf. 2001 Jan; 24(1):1-7. doi: 10.2165/00002018-200124010-00001. PMID: 11219484.

[17]. Hall M, McCormack P, Arthurs N, Feely J. The spontaneous reporting of adverse drug reactions by nurses. Br J Clin Pharmacol. 1995 Aug; 40(2):173-5. doi: 10.1111/j.1365-2125.1995.tb05774.x. PMID: 8562303; PMCID: PMC1365180.

[18]. Hornbuckle, K., Wu, H.-H., & Fung, M. C. (1999). Evaluation of spontaneous adverse event reports by primary reporter—a 15-year review (1983 to 1997). Drug Information Journal, 33(4), 1117–1124.

[19]. WHO (1972) International drug monitoring: the role of national centres. Technical report series WHO 1972, pg. no. 498.

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar–Apr 2025, pp: 2453-2462 www.ijprajournal.com ISSN: 2456-4494

[20]. Collet JP (2000) Limitations of clinical trials. Rev Rrat 50(8):833–837.
[21]. Blenkinsopp A, Wilkie P, Wang M, Routledge PA (2007) Patient reporting of suspected adverse drug reactions: a review of published literature and international experience. Br J Clin Pharmacol 63(2):148–156.
[22]. Gregg WS, Stuart JP (2010) Randomized trials, statistics, and clinical inference. J Am Coll Cardiol 55(5):428–431.
[23]. WHO (2002a) The importance of pharmacovigilance—safety monitoring of medicinal products.
[24]. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000 Oct 7; 356(9237):1255-9. doi: 10.1016/S0140-6736(00)02799-9. PMID: 11072960.
[25]. A.O. Basile, A. Yahi, N.P. Tatonetti, Artificial intelligence for drug toxicity and safety, Trends Pharmacol. Sci. 40 (9) (2019) 624–635, H. Edrees, W. Song, A. Syrowatka, A. Simona, M.G. Amato, D.W. Bates, Intelligent telehealth in pharmacovigilance: a future perspective, Drug Saf. 45 (5) (2022) 449–458,
[26]. J.K. Aronson, Artificial intelligence in pharmacovigilance: an introduction to terms, concepts, applications, and limitations, Drug Saf. 45 (5) (2022) 407–418,
[27]. Y. Li, W. Tao, Z. Li, et al., Artificial intelligence-powered pharmacovigilance: a review of machine and deep learning in clinical text-based adverse drug event detection for benchmark datasets, J. Biomed. Inform. 152 (2024), M. Hauben, Artificial intelligence and data mining for the pharmacovigilance of drug–drug interactions, Clin. Ther. 45 (2) (2023) 117–133F. Salvo, J. Micallef, A. Lahouegue, et al., Will the future of pharmacovigilance be more automated? Expert Opin. Drug Saf. 22 (7) (2023) 541–548, R. Ball, G. Dal Pan, "Artificial intelligence" for pharmacovigilance: ready for prime time? Drug Saf. 45 (5) (2022) 429–438,
[28]. G.L. Martin, J. Jouganous, R. Savidan, et al., Validation of artificial intelligence to support the automatic coding of patient adverse drug reaction reports, using nationwide pharmacovigilance data, Drug Saf. 45 (5) (2022) 535–548,
[29]. J. Schmider, K. Kumar, C. LaForest, B. Swankoski, K. Naim, P.M. Caubel, Innovation in pharmacovigilance: use of artificial intelligence in adverse event case processing, Clin. Pharmacol. Ther. 105 (4) (2018) 954–961
[30]. Muhammad Aasim Shamim, Muhammad Aaqib Shamim, Pankaj Arora, Pradeep Dwivedi, Artificial intelligence and big data for pharmacovigilance and patient safety, Journal of Medicine, Surgery, and Public Health, Volume 3, 2024, 100139, ISSN 2949-916X
[31]. Smith,M. Y., Hammad, T. A., Metcalf, M., Levitan, B.,Noel, R., Wolka, A. M., et al. (2016). Patient engagement at a tipping point-the need for cultural change across patient, sponsor, and regulator stakeholders: insights from the dia conference, "patient engagement in benefit risk assessment throughout the life cycle of medical products". Ther. Innovation Regul. Sci. 50 (5), 546–553. doi:10.1177/2168479016662902.
[32]. Younus, M. M., Alkhakany, M., Bahri, P., Caro, A., Rostom, H., Ndagije, H. B., et al. (2023). The ISoPPatEG-SIG for promoting patient engagement in pharmacovigilance: A change of paradigm is needed. Drug Saf. 46, 619–623. doi:10.1007/s40264-023-01313-4
[33]. Janssens, R., Barbier, L., Muller, M., Cleemput, I., Stoeckert, I., Whichello, C., et al. (2023). How can patient preferences be used and communicated in the regulatory evaluation of medicinal products? Findings and recommendations from IMI PREFER and call to action. Front. Pharmacol. 14, 1192770. doi:10.3389/fphar.2023.1192770
[34]. Hammad, T. A., Neyarapally, G. A., Iyasu, S., Staffa, J. A., and Dal Pan, G. (2013). The future of population-based postmarket drug risk assessment: A regulator's perspective. Clin. Pharmacol. Ther. 94 (3), 349–358. doi:10.1038/clpt.2013.118
[35]. Hammad, T. A., and Pinto, C. A. (2016). Key changes in benefit-risk assessment guidelines: methodological and analytical considerations for drug development.

Statistics Biopharm. Res. 8, 366–372. doi:10.1080/19466315.2016.1201001

[36]. Marsh, K., Ijzerman, M., Thokala, P., Baltussen, R., Boysen, M., Kaló, Z., et al. (2016). Multiple criteria decision analysis for health care decision making–emerging good practices: report 2 of the ispormcda emerging good practices task force. Value Health 19, 125–137. doi:10.1016/j.jval.2015.12.016

[37]. Tervonen, T., Veldwijk, J., Payne, K., Ng, X., Levitan, B., Lackey, L. G., et al. (2023). Quantitative benefit-risk assessment in medical product decision making: A good practices report of an ispor task force. Value Health 26 (4), 449–460. doi:10.1016/j.jval.2022.12.006

[38]. Vermersch, P., Martinelli, V., Pfleger, C., Rieckmann, P., Alonso-Magdalena, L., Galazka, A., et al. (2019). Benefit-risk assessment of cladribine using multi-criteria decision analysis (MCDA) for patients with relapsing-remitting multiple sclerosis. Clin. Ther. 41 (2), 249–260. doi:10.1016/j.clinthera.2018.12.015

[39]. Liang L, Hu J, Sun G, et al. Artificial intelligence-based pharmacovigilance in the setting of limited resources. Drug Saf 2022; 45(5): 511–519.

[40]. Adedeji WA, Adegoke AB and Fehintola FA. Adverse drug reactions reporting practice and associated factors among community health extension workers in public health facilities, Southwest, Nigeria. Pan Afr Med J 2021; 40: 165.

[41]. Suku CK, Hill G, Sabblah G, et al. Experiences and lessons from implementing cohort event monitoring programmes for antimalarials in four African countries: results of a questionnairebased survey. Drug Saf 2015; 38(11):1115–1126.